The Ophthalmic Technology Platform for Developing Drug and Drug Delivery System

Exhibitor: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE

Booth No: R529

Characteristic

Ophthalmic drug is a niche market, but the preclinical facility is not prepared for Taiwan Biotech. ITRI established an one-stop platform for drug design & synthesis / pharmacodynamics / pharmacokinetics / toxicology / pilot & GMP production. Hence, two preclinical drug candidates were generated. One is a novel IOP reducing agent for glaucoma that is effective in reducing intraocular pressure (IOP) and preventing eye irritation. The drug works by relaxing the eye‘s trabecular meshwork (TM) and allowing the aqueous humor (AH) to flow out, thereby lowering the IOP. Another is a delivery system in eye drop form with a high drug solubility and superior delivery efficiency in posterior eye. It is used for the treatment of wet age-related macular degeneration (wet AMD).
Pre-clinical studies for preparing phase I IND package have been completed and the technology has been transferred to pharmaceutical companies in Taiwan. This innovation makes an advance in glaucoma treatment and is expected to drive the pharmaceutical industry to capture the niche market of ophthalmic drugs.